Mesenchymal stem cell therapy for COVID-19 infection

COVID-19 emerged in December 2019 in Wuhan, China, spread worldwide rapidly, and caused millions of deaths in a short time. Many preclinical and clinical studies were performed to discover the most efficient therapy to reduce the mortality of COVID-19 patients. Among various approaches for preventin...

Full description

Saved in:
Bibliographic Details
Published inInflammopharmacology Vol. 32; no. 1; pp. 319 - 334
Main Authors Alavi-Dana, Seyyed Mohammad Matin, Gholami, Yazdan, Meghdadi, Mohammadreza, Fadaei, Mohammad Saleh, Askari, Vahid Reza
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.02.2024
Subjects
Allergology
Biomedical and Life Sciences
Biomedicine
China
COVID-19 - therapy
Cytokine Release Syndrome
Dermatology
Gastroenterology
Humans
Immunology
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells
Pharmacology/Toxicology
Review
Rheumatology
China
COVID-19
Infection
Inflammation
Fibrosis
Cytokine
Mesenchymal stem cells
Online AccessGet full text

Cover

Abstract COVID-19 emerged in December 2019 in Wuhan, China, spread worldwide rapidly, and caused millions of deaths in a short time. Many preclinical and clinical studies were performed to discover the most efficient therapy to reduce the mortality of COVID-19 patients. Among various approaches for preventing and treating COVID-19, mesenchymal stem cell (MSC) therapy can be regarded as a novel and efficient treatment for managing COVID-19 patients. In this review, we explain the pathogenesis of COVID-19 infection in humans and discuss the role of MSCs in suppressing the inflammation and cytokine storm produced by COVID-19. Then, we reviewed the clinical trial and systematic review studies that investigated the safety and efficacy of MSC therapy in the treatment of COVID-19 infection.
AbstractList COVID-19 emerged in December 2019 in Wuhan, China, spread worldwide rapidly, and caused millions of deaths in a short time. Many preclinical and clinical studies were performed to discover the most efficient therapy to reduce the mortality of COVID-19 patients. Among various approaches for preventing and treating COVID-19, mesenchymal stem cell (MSC) therapy can be regarded as a novel and efficient treatment for managing COVID-19 patients. In this review, we explain the pathogenesis of COVID-19 infection in humans and discuss the role of MSCs in suppressing the inflammation and cytokine storm produced by COVID-19. Then, we reviewed the clinical trial and systematic review studies that investigated the safety and efficacy of MSC therapy in the treatment of COVID-19 infection.
Author Askari, Vahid Reza
Alavi-Dana, Seyyed Mohammad Matin
Gholami, Yazdan
Fadaei, Mohammad Saleh
Meghdadi, Mohammadreza
Author_xml – sequence: 1
  givenname: Seyyed Mohammad Matin
  surname: Alavi-Dana
  fullname: Alavi-Dana, Seyyed Mohammad Matin
  organization: Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences
– sequence: 2
  givenname: Yazdan
  surname: Gholami
  fullname: Gholami, Yazdan
  organization: Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences
– sequence: 3
  givenname: Mohammadreza
  surname: Meghdadi
  fullname: Meghdadi, Mohammadreza
  organization: Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences
– sequence: 4
  givenname: Mohammad Saleh
  surname: Fadaei
  fullname: Fadaei, Mohammad Saleh
  organization: Applied Biomedical Research Center, Mashhad University of Medical Sciences
– sequence: 5
  givenname: Vahid Reza
  orcidid: 0000-0001-9268-6270
  surname: Askari
  fullname: Askari, Vahid Reza
  email: askariv@mums.ac.ir, vahidrezaaskary@gmail.com
  organization: Applied Biomedical Research Center, Mashhad University of Medical Sciences, Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38117433$$D View this record in MEDLINE/PubMed
BookMark eNp9kElPwzAQhS1URBf4AxxQjlwM4yW2c0Rlq1TUC3C1HMemqbIUOzn035MS4MhppJn3nuZ9czRp2sYhdEnghgDI20hAKomBMgyEZRyrEzQjqVA4FaAmaAYZTTEXGZ2ieYw7ABBSZGdoyhQhkjM2Q_zFRdfY7aE2VRI7VyfWVVXSbV0w-0Pi25AsN--re0yypGy8s13ZNufo1JsquoufuUBvjw-vy2e83jytlndrbBmXHc6Bei-9Eh4KyyUvjAIpaCqKjOWFG9ZU5NwAMTa3Jue2UCoTnKYFs0owwhboeszdh_azd7HTdRmP_5nGtX3UNANO0qGwHKR0lNrQxhic1_tQ1iYcNAF9pKVHWnqgpb9paTWYrn7y-7x2xZ_lF88gYKMgDqfmwwW9a_vQDJ3_i_0CRJ51SA
CitedBy_id crossref_primary_10_1016_j_bbrc_2024_149973
crossref_primary_10_3390_ijms25010547
crossref_primary_10_4251_wjgo_v16_i5_2113
Cites_doi 10.12998/wjcc.v10.i27.9714
10.3389/fimmu.2022.932360
10.1186/s13287-022-02812-4
10.1016/j.jiph.2022.07.001
10.1177/09636897211024942
10.1016/j.ebiom.2021.103789
10.3892/etm.2021.10444
10.1186/s13287-022-02796-1
10.1002/sctm.21-0046
10.3389/fendo.2021.631463
10.1038/s41392-021-00754-6
10.1016/j.jmii.2020.03.022
10.3389/fimmu.2021.726909
10.1186/s13287-022-02953-6
10.1016/j.arcmed.2020.05.012
10.3389/fimmu.2021.749192
10.1016/j.eclinm.2022.101545
10.1016/j.rmed.2010.04.015
10.1007/s12015-022-10398-w
10.4252/wjsc.v6.i5.552
10.1186/s13287-022-02900-5
10.1038/srep28250
10.1089/scd.2021.0179
10.1186/s13287-021-02165-4
10.1016/j.mehy.2020.109845
10.1155/2022/9346939
10.1089/scd.2018.0256
10.1093/rheumatology/kel267
10.1155/2015/632902
10.1155/2012/812693
10.1186/s13287-019-1471-y
10.1038/s41598-018-25700-5
10.3389/fmed.2021.737590
10.3390/jcm10132991
10.1136/ard.2008.101881
10.1002/ctm2.297
10.4252/wjsc.v6.i3.256
10.1371/journal.ppat.1008762
10.1186/s13054-022-03930-4
10.1089/scd.2020.0080
10.1007/s00018-017-2473-5
10.1093/stcltm/szac032
10.1186/scrt216
10.1002/sctm.20-0472
10.1186/s13287-021-02483-7
10.1038/s41392-020-00286-5
10.1007/s12015-021-10214-x
10.1186/s13287-020-01849-7
10.1186/scrt75
10.1183/13993003.00607-2020
10.1016/j.lfs.2020.118493
10.1016/j.ebiom.2023.104600
10.1186/s41256-022-00251-5
10.1016/j.tranon.2020.100948
10.1016/j.eclinm.2020.100454
10.1186/s13287-022-02920-1
10.1155/2019/9628536
10.1517/14712598.2015.1051528
10.1111/bjh.18292
10.1186/s13287-020-01875-5
10.1186/s13287-022-02771-w
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Copyright_xml – notice: The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1007/s10787-023-01394-8
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1568-5608
EndPage 334
ExternalDocumentID 10_1007_s10787_023_01394_8
38117433
Genre Journal Article
Review
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
-4W
-56
-5G
-BR
-EM
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
1N0
1SB
2.D
203
28-
29I
29~
2J2
2JN
2JY
2KG
2KM
2LR
2VQ
2~H
30V
36B
4.4
406
408
40D
40E
53G
5GY
5VS
67Z
6NX
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AABYN
AAFGU
AAHNG
AAIAL
AAJKR
AANXM
AANZL
AARHV
AARTL
AATNV
AATVU
AAUYE
AAWCG
AAXJT
AAYFA
AAYIU
AAYQN
AAYTO
ABAKF
ABBBX
ABDBF
ABDZT
ABECU
ABELW
ABFGW
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKAS
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABULA
ABWNU
ABXPI
ACAOD
ACBMV
ACBRV
ACBYP
ACGFS
ACHSB
ACHXU
ACIGE
ACIPQ
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACSNA
ACTTH
ACVWB
ACWMK
ACZOJ
ADHHG
ADHIR
ADINQ
ADJJI
ADKNI
ADKPE
ADMDM
ADOAH
ADOXG
ADRFC
ADTPH
ADURQ
ADYFF
ADYPR
ADZKW
AEBTG
AEEQQ
AEFTE
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AESTI
AETLH
AEVLU
AEVTX
AEVUW
AEXYK
AFEXP
AFLOW
AFNRJ
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGBP
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHSBF
AHYZX
AIAKS
AIIXL
AILAN
AIMYW
AITGF
AJBLW
AJDOV
AJRNO
AJZVZ
AKMHD
AKQUC
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMFWP
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
AOSHJ
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
B0M
BA0
BBWZM
BDATZ
BGNMA
CAG
COF
CS3
CSCUP
DDRTE
DNIVK
DPUIP
DU5
EAP
EAS
EBLON
EBS
EIOEI
EJD
EMB
EMK
EMOBN
EN4
ESBYG
EST
ESX
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
HF~
HG5
HG6
HMJXF
HRMNR
HVGLF
HZ~
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JZLTJ
KAT
KDC
KOV
KPH
LLZTM
M4Y
MA-
MK0
N2Q
NB0
NDZJH
NF0
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OVD
P19
P9S
PF0
PT4
PT5
QOK
QOR
QOS
R4E
R89
R9I
RHV
RNI
ROL
RPX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SBL
SBY
SCLPG
SDH
SDM
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
TUS
U2A
U9L
UG4
UNUBA
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WK8
YLTOR
Z45
Z7U
Z7W
Z87
Z8O
Z8Q
Z91
ZMTXR
ZOVNA
~8M
~A9
~EX
AACDK
AAEOY
AAJBT
AAQLM
AASML
AAYZH
ACDTI
AEFQL
AFBBN
AGRTI
AIGIU
CGR
CUY
CVF
ECM
EIF
H13
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c347t-b02ff7f86f0dc474da8076256d93bde6f026b4a01acbcab4cd8896425d3c86313
IEDL.DBID U2A
ISSN 0925-4692
IngestDate Fri Oct 25 06:37:29 EDT 2024
Thu Sep 12 20:08:27 EDT 2024
Sat Nov 02 12:25:40 EDT 2024
Sat Mar 02 01:28:00 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords COVID-19
Infection
Inflammation
Fibrosis
Cytokine
Mesenchymal stem cells
Language English
License 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c347t-b02ff7f86f0dc474da8076256d93bde6f026b4a01acbcab4cd8896425d3c86313
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ORCID 0000-0001-9268-6270
PMID 38117433
PQID 2904155687
PQPubID 23479
PageCount 16
ParticipantIDs proquest_miscellaneous_2904155687
crossref_primary_10_1007_s10787_023_01394_8
pubmed_primary_38117433
springer_journals_10_1007_s10787_023_01394_8
PublicationCentury 2000
PublicationDate 2024-02-01
PublicationDateYYYYMMDD 2024-02-01
PublicationDate_xml – month: 02
  year: 2024
  text: 2024-02-01
  day: 01
PublicationDecade 2020
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: Switzerland
PublicationSubtitle Experimental and Therapeutic Studies
PublicationTitle Inflammopharmacology
PublicationTitleAbbrev Inflammopharmacol
PublicationTitleAlternate Inflammopharmacology
PublicationYear 2024
Publisher Springer International Publishing
Publisher_xml – name: Springer International Publishing
References Fathi-Kazerooni, Fattah-Ghazi, Darzi, Makarem, Nasiri, Salahshour, Dehghan-Manshadi, Kazemnejad (CR16) 2022; 13
Li, Xia, Gao, Chen, Xu (CR29) 2015; 15
Li, Zhao, Wang (CR31) 2021; 14
Aghayan, Salimian, Abedini, Fattah Ghazi, Yunesian, Alavi-Moghadam, Makarem, Majidzadeh-A, Hatamkhani, Moghri (CR2) 2022; 13
Zhu, Shi, Monsel, Dai, Dong, Shen, Li, Chang, Xu, Li (CR61) 2022; 13
Satarker, Nampoothiri (CR48) 2020; 51
CR35
Lanzoni, Linetsky, Correa, Messinger Cayetano, Alvarez, Kouroupis, Alvarez Gil, Poggioli, Ruiz, Marttos (CR25) 2021; 10
Grégoire, Layios, Lambermont, Lechanteur, Briquet, Bettonville, Baudoux, Thys, Dardenne, Misset, Beguin (CR18) 2022; 13
CR33
Luz-Crawford, Kurte, Bravo-Alegría, Contreras, Nova-Lamperti, Tejedor, Noël, Jorgensen, Figueroa, Djouad (CR34) 2013; 4
Bocelli-Tyndall, Bracci, Spagnoli, Braccini, Bouchenaki, Ceredig, Pistoia, Martin, Tyndall (CR7) 2007; 46
Duffy, Ritter, Ceredig, Griffin (CR14) 2011; 2
Karyana, Djaharuddin, Rif'ati, Arif, Choi, Angginy, Yoon, Han, Josh, Arlinda, Narulita, Muchtar, Bakri, Irmansyah (CR22) 2022; 13
Wang, Shi, Chen, Wang, Wang, Feng, Zhang (CR55) 2021; 30
Xu, Jiang, Chen, Xu, Zhang, Zhu, Ye, Li, Yu, Zhou (CR57) 2021; 11
Adas, Cukurova, Yasar, Yilmaz, Isiksacan, Kasapoglu, Yesilbag, Koyuncu, Karaoz (CR1) 2021; 30
Javed, Karki, Sami, Khan, Shree, Sah, Ghosh, Saxena (CR20) 2022; 2022
Sengupta, Sengupta, Lazo, Woods, Nolan, Bremer (CR49) 2020; 29
Gonzalez-Rey, Gonzalez, Varela, O’Valle, Hernandez-Cortes, Rico, Büscher, Delgado (CR17) 2010; 69
Kaffash Farkhad, Sedaghat, Reihani, Adhami Moghadam, Bagheri Moghadam, Khadem Ghaebi, Khodadoust, Ganjali, Tafreshian, Tavakol-Afshari (CR21) 2022; 13
Chu, Wang, Bian, Huang, Wu, Zhang, Fei, Chen, Xia (CR11) 2022; 18
Qu, Wang, Engelberg-Cook, Yan, Siddik, Bu, Allickson, Kubrova, Caplan, Hare (CR41) 2022; 11
Li, Zhang, Fang, Shi, Yao, Li, Zhang, Song, Huang, Xu (CR32) 2023; 92
Arabpour, Khoshdel, Tabatabaie, Akhgarzad, Zangiabadian, Nasiri (CR4) 2021; 8
CR47
Baer (CR5) 2014; 6
Mittal, Manjunath, Ranjan, Kaushik, Kumar, Verma (CR37) 2020; 16
Shen, Huang, Liu, Tian, Wang, Rui (CR50) 2021; 12
Shi, Wang, Xu, Zhang, Xie, Liu, Li, Hu, Zhen, Wang (CR51) 2021; 6
Sanabria-de la Torre, Quiñones-Vico, Fernández-González, Sánchez-Díaz, Montero-Vílchez, Sierra-Sánchez, Arias-Santiago (CR46) 2021; 10
Sadeghi, Soudi, Shafiee, Hashemi (CR44) 2020; 262
Cao, You, Wu, Luo, Wang (CR9) 2022; 10
Dilogo, Aditianingsih, Sugiarto, Burhan, Damayanti, Sitompul, Mariana, Antarianto, Liem, Kispa (CR13) 2021; 10
Yao, Dong, Qi, Zhang, Shi (CR58) 2022; 51
Zhang, Yan, Shi, Li, Pi, Ren, Wang, Yan, Wang, Jin (CR60) 2022; 7
Lee, Choi, Cha, Hwang (CR26) 2015; 2015
Kavianpour, Saleh, Verdi (CR23) 2020; 11
Zhang, Ding, Ren, Wang, Yang, Li, Meng, Wu, Liu, Tian (CR59) 2020; 11
Li, He, Qian, Liu (CR30) 2021; 22
Mousavizadeh, Ghasemi (CR39) 2021; 54
Leuning, Beijer, Du Fossé, Vermeulen, Lievers, Van Kooten, Rabelink, Boer (CR27) 2018; 8
Shu, Niu, Li, Huang, Wang, Huang, Ji, Zheng, Chen, Shi (CR53) 2020; 11
Baer, Geiger (CR6) 2012; 2012
Chen, Chen, Hsu, Chao, Lai (CR10) 2022
Nachmias, Zimran, Avni (CR40) 2022; 199
De Klerk, Hebrok (CR12) 2021; 12
Monsel, Hauw-Berlemont, Mebarki, Heming, Mayaux, Nguekap Tchoumba, Diehl, Demoule, Annane, Marois (CR38) 2022; 26
Rebelatto, Senegaglia, Franck, Daga, Shigunov, Stimamiglio, Marsaro, Schaidt, Micosky, de Azambuja, Leitão, Petterle, Jamur, Vaz, Mallmann, Carraro Junior, Ditzel, Brofman, Correa (CR43) 2022; 13
Kyurkchiev, Bochev, Ivanova-Todorova, Mourdjeva, Oreshkova, Belemezova, Kyurkchiev (CR24) 2014; 6
Cai, Shen, Song, Lu, Wang, Zhao, Tang, Meng, Li, He (CR8) 2016; 6
Ercelen, Pekkoc-Uyanik, Alpaydin, Gulay, Simsek (CR15) 2021; 17
Antoniou, Papadaki, Soufla, Kastrinaki, Damianaki, Koutala, Spandidos, Siafakas (CR3) 2010; 104
Wang, Li, Xu, Deng, Zhao, Yang, Liu, Yuan, Sun, Zhang (CR56) 2021; 12
Wang, Tian, Wang, Heng, Zhou, Cai, Liu (CR54) 2019; 28
Shi, Yuan, Yao, Wang, Zhang, Zhang, Song, Huang, Xu, Fu, Li, Xu, Li, Dong, Cai, Li, Xie, Shi, Li, Wang (CR52) 2022; 75
Li, Hua (CR28) 2017; 74
Rao, Thakur, Rao, Arakeri, Brennan, Jadhav, Sayeed, Rao (CR42) 2020; 143
Saleh, Vaezi, Aliannejad, Sohrabpour, Kiaei, Shadnoush, Siavashi, Aghaghazvini, Khoundabi, Abdoli (CR45) 2021; 12
Hashemian, Aliannejad, Zarrabi, Soleimani, Vosough, Hosseini, Hossieni, Keshel, Naderpour, Hajizadeh-Saffar (CR19) 2021; 12
Meng, Xu, Wang, Xu, Zhang, Li, Yang, Shi, Fu, Jiang (CR36) 2020; 5
HR Aghayan (1394_CR2) 2022; 13
S Sadeghi (1394_CR44) 2020; 262
PC Baer (1394_CR6) 2012; 2012
M Karyana (1394_CR22) 2022; 13
S-MR Hashemian (1394_CR19) 2021; 12
M Chu (1394_CR11) 2022; 18
N Li (1394_CR28) 2017; 74
JX Cao (1394_CR9) 2022; 10
1394_CR35
1394_CR33
A Monsel (1394_CR38) 2022; 26
L Shu (1394_CR53) 2020; 11
M Kavianpour (1394_CR23) 2020; 11
A Mittal (1394_CR37) 2020; 16
L Shi (1394_CR52) 2022; 75
W Yao (1394_CR58) 2022; 51
M Zhang (1394_CR60) 2022; 7
V Sengupta (1394_CR49) 2020; 29
IH Dilogo (1394_CR13) 2021; 10
A Javed (1394_CR20) 2022; 2022
S Lee (1394_CR26) 2015; 2015
ON Ercelen (1394_CR15) 2021; 17
MM Duffy (1394_CR14) 2011; 2
1394_CR47
C Bocelli-Tyndall (1394_CR7) 2007; 46
V Rao (1394_CR42) 2020; 143
C-Y Chen (1394_CR10) 2022
R Sanabria-de la Torre (1394_CR46) 2021; 10
L Wang (1394_CR56) 2021; 12
N Kaffash Farkhad (1394_CR21) 2022; 13
T Li (1394_CR29) 2015; 15
M Saleh (1394_CR45) 2021; 12
E Arabpour (1394_CR4) 2021; 8
E Gonzalez-Rey (1394_CR17) 2010; 69
L Shi (1394_CR51) 2021; 6
C Li (1394_CR31) 2021; 14
DG Leuning (1394_CR27) 2018; 8
J Wang (1394_CR55) 2021; 30
X Xu (1394_CR57) 2021; 11
S Satarker (1394_CR48) 2020; 51
L Mousavizadeh (1394_CR39) 2021; 54
F Meng (1394_CR36) 2020; 5
T-T Li (1394_CR32) 2023; 92
Y Zhang (1394_CR59) 2020; 11
G Lanzoni (1394_CR25) 2021; 10
CLK Rebelatto (1394_CR43) 2022; 13
E De Klerk (1394_CR12) 2021; 12
Y-G Zhu (1394_CR61) 2022; 13
Z Shen (1394_CR50) 2021; 12
KM Antoniou (1394_CR3) 2010; 104
G Adas (1394_CR1) 2021; 30
C Grégoire (1394_CR18) 2022; 13
D Kyurkchiev (1394_CR24) 2014; 6
W Qu (1394_CR41) 2022; 11
M Fathi-Kazerooni (1394_CR16) 2022; 13
P Luz-Crawford (1394_CR34) 2013; 4
M Cai (1394_CR8) 2016; 6
B Nachmias (1394_CR40) 2022; 199
Y Wang (1394_CR54) 2019; 28
C Li (1394_CR30) 2021; 22
PC Baer (1394_CR5) 2014; 6
References_xml – volume: 10
  start-page: 9714
  issue: 27
  year: 2022
  end-page: 9726
  ident: CR9
  article-title: Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review
  publication-title: World J Clin Cases
  doi: 10.12998/wjcc.v10.i27.9714
  contributor:
    fullname: Wang
– volume: 17
  start-page: 1917
  year: 2021
  end-page: 1925
  ident: CR15
  article-title: Clinical experience on umbilical cord mesenchymal stem cell treatment in 210 severe and critical COVID-19 cases in Turkey
  publication-title: Stem Cell Rev Rep
  contributor:
    fullname: Simsek
– volume: 29
  start-page: 747
  issue: 12
  year: 2020
  end-page: 754
  ident: CR49
  article-title: Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19
  publication-title: Stem Cells Dev
  contributor:
    fullname: Bremer
– volume: 13
  year: 2022
  ident: CR18
  article-title: Bone marrow-derived mesenchymal stromal cell therapy in severe COVID-19: preliminary results of a phase I/II clinical trial
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.932360
  contributor:
    fullname: Beguin
– volume: 10
  start-page: 2991
  issue: 13
  year: 2021
  ident: CR46
  article-title: Alloreactive immune response associated to human mesenchymal stromal cells treatment: a systematic review
  publication-title: J Clin Med
  contributor:
    fullname: Arias-Santiago
– volume: 2022
  start-page: 1
  year: 2022
  end-page: 17
  ident: CR20
  article-title: Association between mesenchymal stem cells and covid-19 therapy: systematic review and current trends
  publication-title: BioMed Res Int
  contributor:
    fullname: Saxena
– volume: 12
  year: 2021
  ident: CR56
  article-title: Regulation of inflammatory cytokine storms by mesenchymal stem cells
  publication-title: Front Immunol
  contributor:
    fullname: Zhang
– volume: 74
  start-page: 2345
  year: 2017
  end-page: 2360
  ident: CR28
  article-title: Interactions between mesenchymal stem cells and the immune system
  publication-title: Cell Mol Life Sci
  contributor:
    fullname: Hua
– volume: 46
  start-page: 403
  issue: 3
  year: 2007
  end-page: 408
  ident: CR7
  article-title: Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous-and allogeneic-stimulated lymphocytes in vitro
  publication-title: Rheumatology
  contributor:
    fullname: Tyndall
– volume: 2012
  start-page: 1
  year: 2012
  end-page: 11
  ident: CR6
  article-title: Adipose-derived mesenchymal stromal/stem cells: tissue localization, characterization, and heterogeneity
  publication-title: Stem Cells Int
  contributor:
    fullname: Geiger
– volume: 12
  start-page: 1
  issue: 1
  year: 2021
  end-page: 12
  ident: CR19
  article-title: Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series
  publication-title: Stem Cell Res Ther
  contributor:
    fullname: Hajizadeh-Saffar
– ident: CR35
– volume: 13
  start-page: 134
  issue: 1
  year: 2022
  ident: CR22
  article-title: Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-022-02812-4
  contributor:
    fullname: Irmansyah
– volume: 12
  start-page: 1
  issue: 1
  year: 2021
  end-page: 13
  ident: CR45
  article-title: Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial
  publication-title: Stem Cell Res Ther
  contributor:
    fullname: Abdoli
– volume: 4
  start-page: 1
  year: 2013
  end-page: 12
  ident: CR34
  article-title: Mesenchymal stem cells generate a CD4+ CD25+ Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells
  publication-title: Stem Cell Res Ther
  contributor:
    fullname: Djouad
– volume: 2
  start-page: 1
  year: 2011
  end-page: 9
  ident: CR14
  article-title: Mesenchymal stem cell effects on T-cell effector pathways
  publication-title: Stem Cell Res Ther
  contributor:
    fullname: Griffin
– volume: 11
  start-page: 1
  issue: 1
  year: 2020
  end-page: 11
  ident: CR53
  article-title: Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
  publication-title: Stem Cell Res Ther
  contributor:
    fullname: Shi
– volume: 16
  issue: 8
  year: 2020
  ident: CR37
  article-title: COVID-19 pandemic: insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2
  publication-title: PLoS Pathog
  contributor:
    fullname: Verma
– volume: 11
  start-page: 1
  year: 2020
  end-page: 6
  ident: CR59
  article-title: Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia
  publication-title: Stem Cell Res Ther
  contributor:
    fullname: Tian
– volume: 8
  start-page: 7716
  issue: 1
  year: 2018
  ident: CR27
  article-title: The cytokine secretion profile of mesenchymal stromal cells is determined by surface structure of the microenvironment
  publication-title: Sci Rep
  contributor:
    fullname: Boer
– volume: 28
  start-page: 1141
  issue: 17
  year: 2019
  end-page: 1150
  ident: CR54
  article-title: Understanding the immunological mechanisms of mesenchymal stem cells in allogeneic transplantation: from the aspect of major histocompatibility complex class I
  publication-title: Stem Cells Dev
  contributor:
    fullname: Liu
– volume: 8
  year: 2021
  ident: CR4
  article-title: Stem cells therapy for COVID-19: a systematic review and meta-analysis
  publication-title: Front Med
  contributor:
    fullname: Nasiri
– volume: 143
  year: 2020
  ident: CR42
  article-title: Mesenchymal stem cells-bridge catalyst between innate and adaptive immunity in COVID 19
  publication-title: Med Hypoth
  contributor:
    fullname: Rao
– volume: 13
  start-page: 1
  issue: 1
  year: 2022
  end-page: 10
  ident: CR61
  article-title: Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study
  publication-title: Stem Cell Res Ther
  contributor:
    fullname: Li
– volume: 13
  start-page: 96
  issue: 1
  year: 2022
  ident: CR16
  article-title: Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II
  publication-title: Stem Cell Res Ther
  contributor:
    fullname: Kazemnejad
– volume: 104
  start-page: 1535
  issue: 10
  year: 2010
  end-page: 1542
  ident: CR3
  article-title: Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in idiopathic pulmonary fibrosis (IPF)
  publication-title: Respir Med
  contributor:
    fullname: Siafakas
– volume: 10
  start-page: 1279
  issue: 9
  year: 2021
  end-page: 1287
  ident: CR13
  article-title: Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial
  publication-title: Stem Cells Transl Med
  contributor:
    fullname: Kispa
– year: 2022
  ident: CR10
  article-title: The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
  publication-title: J Infect Public Health
  doi: 10.1016/j.jiph.2022.07.001
  contributor:
    fullname: Lai
– volume: 30
  start-page: 947
  issue: 19
  year: 2021
  end-page: 969
  ident: CR55
  article-title: Research status of the safety and efficacy of mesenchymal stem cells in the treatment of COVID-19-related pneumonia: a systematic review and meta-analysis
  publication-title: Stem Cells Dev
  contributor:
    fullname: Zhang
– volume: 12
  year: 2021
  ident: CR12
  article-title: Stem cell-based clinical trials for diabetes mellitus
  publication-title: Front Endocrinol
  contributor:
    fullname: Hebrok
– volume: 10
  start-page: 660
  issue: 5
  year: 2021
  end-page: 673
  ident: CR25
  article-title: Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial
  publication-title: Stem Cells Transl Med
  contributor:
    fullname: Marttos
– volume: 11
  start-page: 688
  issue: 7
  year: 2022
  end-page: 703
  ident: CR41
  article-title: Efficacy and safety of MSC cell therapies for hospitalized patients with COVID-19: a systematic review and meta-analysis
  publication-title: Stem Cells Transl Med
  contributor:
    fullname: Hare
– volume: 7
  start-page: 1
  issue: 1
  year: 2022
  end-page: 13
  ident: CR60
  article-title: Safety and efficiency of stem cell therapy for COVID-19: a systematic review and meta-analysis
  publication-title: Global Health Res Policy
  contributor:
    fullname: Jin
– volume: 6
  start-page: 256
  issue: 3
  year: 2014
  ident: CR5
  article-title: Adipose-derived mesenchymal stromal/stem cells: an update on their phenotype in vivo and in vitro
  publication-title: World J Stem Cells
  contributor:
    fullname: Baer
– volume: 12
  year: 2021
  ident: CR50
  article-title: Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases
  publication-title: Front Immunol
  contributor:
    fullname: Rui
– volume: 69
  start-page: 241
  issue: 01
  year: 2010
  end-page: 248
  ident: CR17
  article-title: Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Delgado
– volume: 14
  issue: 1
  year: 2021
  ident: CR31
  article-title: Mesenchymal stem/stromal cells: developmental origin, tumorigenesis and translational cancer therapeutics
  publication-title: Transl Oncol
  contributor:
    fullname: Wang
– volume: 5
  start-page: 172
  issue: 1
  year: 2020
  ident: CR36
  article-title: Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial
  publication-title: Signal Transduct Target Ther
  contributor:
    fullname: Jiang
– volume: 15
  start-page: 1293
  issue: 9
  year: 2015
  end-page: 1306
  ident: CR29
  article-title: Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy
  publication-title: Expert Opin Biol Ther
  contributor:
    fullname: Xu
– volume: 54
  start-page: 159
  issue: 2
  year: 2021
  end-page: 163
  ident: CR39
  article-title: Genotype and phenotype of COVID-19: their roles in pathogenesis
  publication-title: J Microbiol Immunol Infect
  contributor:
    fullname: Ghasemi
– volume: 30
  start-page: 9636897211024942
  year: 2021
  ident: CR1
  article-title: The systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial
  publication-title: Cell Transplant
  doi: 10.1177/09636897211024942
  contributor:
    fullname: Karaoz
– volume: 13
  start-page: 283
  issue: 1
  year: 2022
  ident: CR21
  article-title: Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial
  publication-title: Stem Cell Res Ther
  contributor:
    fullname: Tavakol-Afshari
– volume: 6
  start-page: 339
  issue: 1
  year: 2021
  ident: CR51
  article-title: Mesenchymal stem cell therapy for severe COVID-19
  publication-title: Signal Transduct Target Ther
  contributor:
    fullname: Wang
– volume: 11
  start-page: 1
  issue: 1
  year: 2020
  end-page: 19
  ident: CR23
  article-title: The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm
  publication-title: Stem Cell Res Ther
  contributor:
    fullname: Verdi
– ident: CR47
– volume: 262
  year: 2020
  ident: CR44
  article-title: Mesenchymal stem cell therapies for COVID-19: current status and mechanism of action
  publication-title: Life Sci
  contributor:
    fullname: Hashemi
– volume: 75
  start-page: 103789
  year: 2022
  ident: CR52
  article-title: Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2021.103789
  contributor:
    fullname: Wang
– volume: 2015
  start-page: 1
  year: 2015
  end-page: 9
  ident: CR26
  article-title: Cell adhesion and long-term survival of transplanted mesenchymal stem cells: a prerequisite for cell therapy
  publication-title: Oxidat Med Cell Long
  contributor:
    fullname: Hwang
– ident: CR33
– volume: 11
  issue: 2
  year: 2021
  ident: CR57
  article-title: Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: an exploratory clinical trial
  publication-title: Clin Transl Med
  contributor:
    fullname: Zhou
– volume: 13
  start-page: 1
  issue: 1
  year: 2022
  end-page: 12
  ident: CR2
  article-title: Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment
  publication-title: Stem Cell Res Ther
  contributor:
    fullname: Moghri
– volume: 199
  start-page: 175
  issue: 2
  year: 2022
  end-page: 189
  ident: CR40
  article-title: Mesenchymal stroma/stem cells: haematologists’ friend or foe?
  publication-title: Br J Haematol
  contributor:
    fullname: Avni
– volume: 92
  start-page: 104600
  year: 2023
  ident: CR32
  article-title: Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial
  publication-title: EBioMedicine
  contributor:
    fullname: Xu
– volume: 6
  start-page: 28250
  issue: 1
  year: 2016
  ident: CR8
  article-title: Bone marrow mesenchymal stem cells (BM-MSCs) improve heart function in swine myocardial infarction model through paracrine effects
  publication-title: Sci Rep
  contributor:
    fullname: He
– volume: 6
  start-page: 552
  issue: 5
  year: 2014
  ident: CR24
  article-title: Secretion of immunoregulatory cytokines by mesenchymal stem cells
  publication-title: World J Stem Cells
  contributor:
    fullname: Kyurkchiev
– volume: 22
  start-page: 1011
  issue: 3
  year: 2021
  ident: CR30
  article-title: Overview of the pathogenesis of COVID-19 (Review)
  publication-title: Exp Ther Med
  doi: 10.3892/etm.2021.10444
  contributor:
    fullname: Liu
– volume: 51
  start-page: 101545
  year: 2022
  ident: CR58
  article-title: Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: a systematic review and meta-analysis
  publication-title: EClinicalMedicine
  contributor:
    fullname: Shi
– volume: 13
  start-page: 122
  issue: 1
  year: 2022
  ident: CR43
  article-title: Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-022-02796-1
  contributor:
    fullname: Correa
– volume: 26
  start-page: 48
  issue: 1
  year: 2022
  ident: CR38
  article-title: Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial
  publication-title: Crit Care
  contributor:
    fullname: Marois
– volume: 51
  start-page: 482
  issue: 6
  year: 2020
  end-page: 491
  ident: CR48
  article-title: Structural proteins in severe acute respiratory syndrome coronavirus-2
  publication-title: Arch Med Res
  contributor:
    fullname: Nampoothiri
– volume: 18
  start-page: 2152
  issue: 6
  year: 2022
  end-page: 2163
  ident: CR11
  article-title: Nebulization therapy with umbilical cord mesenchymal stem cell-derived exosomes for COVID-19 pneumonia
  publication-title: Stem Cell Rev Rep
  contributor:
    fullname: Xia
– volume: 13
  start-page: 134
  issue: 1
  year: 2022
  ident: 1394_CR22
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-022-02812-4
  contributor:
    fullname: M Karyana
– volume: 10
  start-page: 1279
  issue: 9
  year: 2021
  ident: 1394_CR13
  publication-title: Stem Cells Transl Med
  doi: 10.1002/sctm.21-0046
  contributor:
    fullname: IH Dilogo
– volume: 12
  year: 2021
  ident: 1394_CR12
  publication-title: Front Endocrinol
  doi: 10.3389/fendo.2021.631463
  contributor:
    fullname: E De Klerk
– volume: 6
  start-page: 339
  issue: 1
  year: 2021
  ident: 1394_CR51
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-021-00754-6
  contributor:
    fullname: L Shi
– volume: 54
  start-page: 159
  issue: 2
  year: 2021
  ident: 1394_CR39
  publication-title: J Microbiol Immunol Infect
  doi: 10.1016/j.jmii.2020.03.022
  contributor:
    fullname: L Mousavizadeh
– volume: 12
  year: 2021
  ident: 1394_CR56
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.726909
  contributor:
    fullname: L Wang
– volume: 30
  start-page: 963689721102494
  year: 2021
  ident: 1394_CR1
  publication-title: Cell Transplant
  doi: 10.1177/09636897211024942
  contributor:
    fullname: G Adas
– volume: 13
  start-page: 1
  issue: 1
  year: 2022
  ident: 1394_CR2
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-022-02953-6
  contributor:
    fullname: HR Aghayan
– volume: 51
  start-page: 482
  issue: 6
  year: 2020
  ident: 1394_CR48
  publication-title: Arch Med Res
  doi: 10.1016/j.arcmed.2020.05.012
  contributor:
    fullname: S Satarker
– volume: 12
  year: 2021
  ident: 1394_CR50
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.749192
  contributor:
    fullname: Z Shen
– volume: 51
  start-page: 101545
  year: 2022
  ident: 1394_CR58
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2022.101545
  contributor:
    fullname: W Yao
– volume: 104
  start-page: 1535
  issue: 10
  year: 2010
  ident: 1394_CR3
  publication-title: Respir Med
  doi: 10.1016/j.rmed.2010.04.015
  contributor:
    fullname: KM Antoniou
– volume: 18
  start-page: 2152
  issue: 6
  year: 2022
  ident: 1394_CR11
  publication-title: Stem Cell Rev Rep
  doi: 10.1007/s12015-022-10398-w
  contributor:
    fullname: M Chu
– volume: 6
  start-page: 552
  issue: 5
  year: 2014
  ident: 1394_CR24
  publication-title: World J Stem Cells
  doi: 10.4252/wjsc.v6.i5.552
  contributor:
    fullname: D Kyurkchiev
– volume: 13
  start-page: 1
  issue: 1
  year: 2022
  ident: 1394_CR61
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-022-02900-5
  contributor:
    fullname: Y-G Zhu
– volume: 6
  start-page: 28250
  issue: 1
  year: 2016
  ident: 1394_CR8
  publication-title: Sci Rep
  doi: 10.1038/srep28250
  contributor:
    fullname: M Cai
– volume: 30
  start-page: 947
  issue: 19
  year: 2021
  ident: 1394_CR55
  publication-title: Stem Cells Dev
  doi: 10.1089/scd.2021.0179
  contributor:
    fullname: J Wang
– volume: 12
  start-page: 1
  issue: 1
  year: 2021
  ident: 1394_CR19
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-021-02165-4
  contributor:
    fullname: S-MR Hashemian
– volume: 143
  year: 2020
  ident: 1394_CR42
  publication-title: Med Hypoth
  doi: 10.1016/j.mehy.2020.109845
  contributor:
    fullname: V Rao
– volume: 2022
  start-page: 1
  year: 2022
  ident: 1394_CR20
  publication-title: BioMed Res Int
  doi: 10.1155/2022/9346939
  contributor:
    fullname: A Javed
– volume: 28
  start-page: 1141
  issue: 17
  year: 2019
  ident: 1394_CR54
  publication-title: Stem Cells Dev
  doi: 10.1089/scd.2018.0256
  contributor:
    fullname: Y Wang
– volume: 46
  start-page: 403
  issue: 3
  year: 2007
  ident: 1394_CR7
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/kel267
  contributor:
    fullname: C Bocelli-Tyndall
– volume: 2015
  start-page: 1
  year: 2015
  ident: 1394_CR26
  publication-title: Oxidat Med Cell Long
  doi: 10.1155/2015/632902
  contributor:
    fullname: S Lee
– volume: 2012
  start-page: 1
  year: 2012
  ident: 1394_CR6
  publication-title: Stem Cells Int
  doi: 10.1155/2012/812693
  contributor:
    fullname: PC Baer
– volume: 10
  start-page: 9714
  issue: 27
  year: 2022
  ident: 1394_CR9
  publication-title: World J Clin Cases
  doi: 10.12998/wjcc.v10.i27.9714
  contributor:
    fullname: JX Cao
– volume: 11
  start-page: 1
  year: 2020
  ident: 1394_CR59
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-019-1471-y
  contributor:
    fullname: Y Zhang
– year: 2022
  ident: 1394_CR10
  publication-title: J Infect Public Health
  doi: 10.1016/j.jiph.2022.07.001
  contributor:
    fullname: C-Y Chen
– volume: 8
  start-page: 7716
  issue: 1
  year: 2018
  ident: 1394_CR27
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-25700-5
  contributor:
    fullname: DG Leuning
– volume: 8
  year: 2021
  ident: 1394_CR4
  publication-title: Front Med
  doi: 10.3389/fmed.2021.737590
  contributor:
    fullname: E Arabpour
– volume: 10
  start-page: 2991
  issue: 13
  year: 2021
  ident: 1394_CR46
  publication-title: J Clin Med
  doi: 10.3390/jcm10132991
  contributor:
    fullname: R Sanabria-de la Torre
– volume: 69
  start-page: 241
  issue: 01
  year: 2010
  ident: 1394_CR17
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2008.101881
  contributor:
    fullname: E Gonzalez-Rey
– volume: 22
  start-page: 1011
  issue: 3
  year: 2021
  ident: 1394_CR30
  publication-title: Exp Ther Med
  doi: 10.3892/etm.2021.10444
  contributor:
    fullname: C Li
– volume: 11
  issue: 2
  year: 2021
  ident: 1394_CR57
  publication-title: Clin Transl Med
  doi: 10.1002/ctm2.297
  contributor:
    fullname: X Xu
– volume: 6
  start-page: 256
  issue: 3
  year: 2014
  ident: 1394_CR5
  publication-title: World J Stem Cells
  doi: 10.4252/wjsc.v6.i3.256
  contributor:
    fullname: PC Baer
– volume: 75
  start-page: 103789
  year: 2022
  ident: 1394_CR52
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2021.103789
  contributor:
    fullname: L Shi
– volume: 16
  issue: 8
  year: 2020
  ident: 1394_CR37
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1008762
  contributor:
    fullname: A Mittal
– volume: 26
  start-page: 48
  issue: 1
  year: 2022
  ident: 1394_CR38
  publication-title: Crit Care
  doi: 10.1186/s13054-022-03930-4
  contributor:
    fullname: A Monsel
– volume: 29
  start-page: 747
  issue: 12
  year: 2020
  ident: 1394_CR49
  publication-title: Stem Cells Dev
  doi: 10.1089/scd.2020.0080
  contributor:
    fullname: V Sengupta
– volume: 13
  year: 2022
  ident: 1394_CR18
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.932360
  contributor:
    fullname: C Grégoire
– volume: 74
  start-page: 2345
  year: 2017
  ident: 1394_CR28
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-017-2473-5
  contributor:
    fullname: N Li
– volume: 11
  start-page: 688
  issue: 7
  year: 2022
  ident: 1394_CR41
  publication-title: Stem Cells Transl Med
  doi: 10.1093/stcltm/szac032
  contributor:
    fullname: W Qu
– volume: 4
  start-page: 1
  year: 2013
  ident: 1394_CR34
  publication-title: Stem Cell Res Ther
  doi: 10.1186/scrt216
  contributor:
    fullname: P Luz-Crawford
– volume: 10
  start-page: 660
  issue: 5
  year: 2021
  ident: 1394_CR25
  publication-title: Stem Cells Transl Med
  doi: 10.1002/sctm.20-0472
  contributor:
    fullname: G Lanzoni
– volume: 12
  start-page: 1
  issue: 1
  year: 2021
  ident: 1394_CR45
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-021-02483-7
  contributor:
    fullname: M Saleh
– volume: 5
  start-page: 172
  issue: 1
  year: 2020
  ident: 1394_CR36
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-020-00286-5
  contributor:
    fullname: F Meng
– volume: 17
  start-page: 1917
  year: 2021
  ident: 1394_CR15
  publication-title: Stem Cell Rev Rep
  doi: 10.1007/s12015-021-10214-x
  contributor:
    fullname: ON Ercelen
– volume: 13
  start-page: 122
  issue: 1
  year: 2022
  ident: 1394_CR43
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-022-02796-1
  contributor:
    fullname: CLK Rebelatto
– volume: 11
  start-page: 1
  issue: 1
  year: 2020
  ident: 1394_CR23
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-020-01849-7
  contributor:
    fullname: M Kavianpour
– volume: 2
  start-page: 1
  year: 2011
  ident: 1394_CR14
  publication-title: Stem Cell Res Ther
  doi: 10.1186/scrt75
  contributor:
    fullname: MM Duffy
– ident: 1394_CR35
  doi: 10.1183/13993003.00607-2020
– volume: 262
  year: 2020
  ident: 1394_CR44
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2020.118493
  contributor:
    fullname: S Sadeghi
– volume: 92
  start-page: 104600
  year: 2023
  ident: 1394_CR32
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2023.104600
  contributor:
    fullname: T-T Li
– volume: 7
  start-page: 1
  issue: 1
  year: 2022
  ident: 1394_CR60
  publication-title: Global Health Res Policy
  doi: 10.1186/s41256-022-00251-5
  contributor:
    fullname: M Zhang
– volume: 14
  issue: 1
  year: 2021
  ident: 1394_CR31
  publication-title: Transl Oncol
  doi: 10.1016/j.tranon.2020.100948
  contributor:
    fullname: C Li
– ident: 1394_CR47
  doi: 10.1016/j.eclinm.2020.100454
– volume: 13
  start-page: 283
  issue: 1
  year: 2022
  ident: 1394_CR21
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-022-02920-1
  contributor:
    fullname: N Kaffash Farkhad
– ident: 1394_CR33
  doi: 10.1155/2019/9628536
– volume: 15
  start-page: 1293
  issue: 9
  year: 2015
  ident: 1394_CR29
  publication-title: Expert Opin Biol Ther
  doi: 10.1517/14712598.2015.1051528
  contributor:
    fullname: T Li
– volume: 199
  start-page: 175
  issue: 2
  year: 2022
  ident: 1394_CR40
  publication-title: Br J Haematol
  doi: 10.1111/bjh.18292
  contributor:
    fullname: B Nachmias
– volume: 11
  start-page: 1
  issue: 1
  year: 2020
  ident: 1394_CR53
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-020-01875-5
  contributor:
    fullname: L Shu
– volume: 13
  start-page: 96
  issue: 1
  year: 2022
  ident: 1394_CR16
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-022-02771-w
  contributor:
    fullname: M Fathi-Kazerooni
SSID ssj0006769
Score 2.4087389
SecondaryResourceType review_article
Snippet COVID-19 emerged in December 2019 in Wuhan, China, spread worldwide rapidly, and caused millions of deaths in a short time. Many preclinical and clinical...
SourceID proquest
crossref
pubmed
springer
SourceType Aggregation Database
Index Database
Publisher
StartPage 319
SubjectTerms Allergology
Biomedical and Life Sciences
Biomedicine
China
COVID-19 - therapy
Cytokine Release Syndrome
Dermatology
Gastroenterology
Humans
Immunology
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells
Pharmacology/Toxicology
Review
Rheumatology
Title Mesenchymal stem cell therapy for COVID-19 infection
URI https://link.springer.com/article/10.1007/s10787-023-01394-8
https://www.ncbi.nlm.nih.gov/pubmed/38117433
https://search.proquest.com/docview/2904155687
Volume 32
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3JTsMwEB1BkRAXxE5ZKiMhLtRS4jiOe6wKZVOhB4rgFHmJxYWAaDn07xlnoaAiJK5RNFaeJ_ZzZt4LwLHz6k5pFM6AspRLm1AVBgFNGNMiw4SwgRc4D27F5YhfP8aPMx130exeVySLhfqb1g1zi-IWQz1r4VQuwhKSB-5PXCPW_Vp-fc9mYbDHYopnP1YpZX6P8XM3mqOYc-XRYtfpr8FqRRdJt5zfdVjI8g1YHlQF8Q04GZbW09M2uZ8pqcZtckKGM1Pq6SbwgZcZmefpC4bz5s3Ef7InpfxqSpC6kt7dw9UZDTukbtDKt2DUP7_vXdLqjwnURDyZUB0w5xInhQus4Qm3Sga42sXCdiJtM7zMhOYqCJXRRmlurJQdPIHENjJSRGG0DY38Nc92gShjMu6QL-rM8sgpKbh2QunY-V7EKGzCaY1c-lYaY6QzC2SPc4o4pwXOqWzCUQ1uivnrn1Dl2evHOGUdbxIQC5k0YadE_Ste5FWwOFgT2vU0pNUrNv5jsL3_3b4PKwyZStmKfQCNyftHdohMY6JbsNS9eLo5bxUZ9gmoI8kF
link.rule.ids 315,783,787,27937,27938,41094,41536,42163,42605,52124,52247
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3JTsMwEB2xSMAFsVNWI6FeqKXEcRz3iAqoLIUeWtSb5SUWF1JE20P-HjsLBYGQuEbRWBlPZp4z814Azq1nd3It3Q5Igyk3CZZhEOCEEMVSFxAm8ATn3iPrDundKB5VpLBJPe1etySLTP2F7OaCC7sagz1soZgvwrLXV_eDfENy-Zl__dBmobBHYuwOf6Siyvxu43s5-oExf_RHi7JzswHrFV5El-UGb8JCmm3BSq_qiG9Bs19qT-ctNJhTqSYt1ET9uSp1vg2053lG-iV_dea8ejPy3-xRyb_KkcOuqPP0fHuFwzaqJ7SyHRjeXA86XVz9MgHriCZTrAJibWI5s4HRNKFG8sClu5iZdqRM6i4TpqgMQqmVlopqw3nbHUFiE2nOojDahaVsnKX7gKTWKbUOMKrU0MhKzqiyTKrY-mHEKGzARe058VYqY4i5BrL3s3B-FoWfBW_AWe1c4QLYP6HM0vFsIkjbqwTEjCcN2Cu9_mkv8jRYt1gDWvU2iOodm_yx2MH_bj-F1e6g9yAebh_vD2GNONhSzmUfwdL0fZYeO9gxVSdFlH0AGezKzA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LTxsxEB6VICEuFCiFtAWMVHFpHPbh9TrHCAjP0BygoifLj7WQEEtENof013ec3SW8VKniulrZ65mx_Y1mvm8BvjvP7hRGoQeUpUzYlKowCGgaRZpnGBA28ATn_gU_vmKn18n1Exb_tNu9LkmWnAav0pQXe0Pr9p4Q3zDQKN431EMYRsUczLMQU5UGzHePfp8dPp7GvoVzqrcXJRRTwagizrw9yvPL6RXifFUtnV5CvY-g6s8ve09u2-NCt82fF8qO71nfMixVCJV0y5BagQ9ZvgoL_aoGvwq7g1LtetIilzPy1qhFdslgpoM9-QSs75lN5mZyh8N5vWjiqwSkZHxNCKJlsv_z18kBDTuk7gnL1-Cqd3i5f0yrnzRQE7O0oDqInEud4C6whqXMKhHgAZtw24m1zfBxxDVTQaiMNkozY4XoYNKT2NgIHofxZ2jk93m2AUQZkzGHEFVnlsVOCc6040onzrc_xmETftTekcNSi0POVJe9xSRaTE4tJkUTdmoHStwyfoUqz-7HIxl1vC5BwkXahPXSs4_jxZ54i5M1oVV7SVa7evSPyb783-vbsDA46Mnzk4uzr7AYIU4qG8G_QaN4GGebiHMKvVWF8l98YvCt
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mesenchymal+stem+cell+therapy+for+COVID-19+infection&rft.jtitle=Inflammopharmacology&rft.au=Alavi-Dana%2C+Seyyed+Mohammad+Matin&rft.au=Gholami%2C+Yazdan&rft.au=Meghdadi%2C+Mohammadreza&rft.au=Fadaei%2C+Mohammad+Saleh&rft.date=2024-02-01&rft.pub=Springer+International+Publishing&rft.issn=0925-4692&rft.eissn=1568-5608&rft.volume=32&rft.issue=1&rft.spage=319&rft.epage=334&rft_id=info:doi/10.1007%2Fs10787-023-01394-8&rft.externalDocID=10_1007_s10787_023_01394_8
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0925-4692&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0925-4692&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0925-4692&client=summon